The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000657325
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
10/04/2026
Date registered
Help: Date registered
3/06/2026
Date last updated
Help: Date last updated
3/06/2026
Date data sharing statement initially provided
Help: Data sharing statement date
3/06/2026
Type of registration
Help: Type of registration
Retrospectively registered

Titles & IDs
Public title
Expanding access to hepatitis C care by offering rapid finger prick testing at community pharmacies for adults with hepatitis C risk factors.
Scientific title
Evaluating the proportion of adults with hepatitis C risk factors who are diagnosed, initiate treatment, and achieve cure following expanded access to point-of-care hepatitis C antibody testing delivered through community pharmacies.
Additional trial identifiers [1] 316896 0
Nil known
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Hepatitis C 341308 0
Condition category
Condition code
Public Health 337381 337381 0 0
Health service research
Infection 338101 338101 0 0
Studies of infection and infectious agents

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
The intervention delivers pharmacist- and nurse-led hepatitis C antibody screening in community pharmacies using a rapid INSTI® point-of-care (POC) finger-stick blood test with results available within one minute. Participants with POC results are supported to access confirmatory hepatitis C RNA testing and antiviral treatment, as indicated, through referral to general practitioners or specialist prescribers, and are invited to consent to follow-up to self-report treatment outcomes and permit confirmation of prescription presentation at the pharmacy they attend.


Intervention code [1] 333600 0
Diagnosis / Prognosis
Description of the comparator or control
Non control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 344900 0
1.The proportion of People Who Inject Drugs tested and test positive to HCV point of care (POC) test, go on to complete confirmatory diagnostic assessment for HCV infection.
Timepoint [1] 344900 0
At study completion, the proportion of participants with a reactive HCV point-of-care test who complete confirmatory diagnostic assessment will be measured.
Primary outcome [2] 345347 0
Proportion of people who inject drugs who initiate and receive treatment for hepatitis C infection.
Timepoint [2] 345347 0
Three months post the pharmacy visit of the participant.
Secondary outcome [1] 459671 0
To determine proportion of treated participants achieving cure.
Timepoint [1] 459671 0
Three months post the pharmacy visit of the participant.

Eligibility
Key inclusion criteria
Inclusion criteria for participation:
1. Aged 18 years and over;
2. Risk factors for hepatitis C (e.g. People who currently or have injected drugs, people from custodial settings, people with tattoos or body piercing outside regulated settings, people who received blood transfusions prior to 1990, people with evidence of liver disease.)
3. Has not had hepatitis C RNA test in the last 12 months
4. Willing and able to provide written informed consent
5. Medicare eligible.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
1. Pregnant or breastfeeding women
2. Unable to read or understand English

Study design
Purpose of the study
Diagnosis
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
ACT,NSW,TAS,VIC

Funding & Sponsors
Funding source category [1] 321491 0
Other
Name [1] 321491 0
Burnet Institute / Health and Medical Research
Country [1] 321491 0
Australia
Primary sponsor type
Other
Name
Burnet Institute / Health and Medical Research
Address
Country
Australia
Secondary sponsor category [1] 324247 0
None
Name [1] 324247 0
Address [1] 324247 0
Country [1] 324247 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320025 0
Alfred Hospital Ethics Committee
Ethics committee address [1] 320025 0
Ethics committee country [1] 320025 0
Australia
Date submitted for ethics approval [1] 320025 0
19/12/2024
Approval date [1] 320025 0
13/02/2025
Ethics approval number [1] 320025 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 149182 0
Prof Joseph Doyle
Address 149182 0
Monash University& Burnet Institute, Commercial Road Melbourne 3000 Melbourne, Victoria
Country 149182 0
Australia
Phone 149182 0
+61 0411 145 119
Fax 149182 0
Email 149182 0
Contact person for public queries
Name 149183 0
Kate Allardice
Address 149183 0
Burnet Institute, Commercial Road Melbourne 3000 Melbourne, Victoria
Country 149183 0
Australia
Phone 149183 0
+61 427 375 844
Fax 149183 0
Email 149183 0
Contact person for scientific queries
Name 149184 0
Joseph Doyle
Address 149184 0
Monash University & Burnet Institute, Commercial Road Melbourne 3000 Melbourne, Victoria
Country 149184 0
Australia
Phone 149184 0
+61 039282 2111
Fax 149184 0
Email 149184 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.